The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes Cloudy, thanks.
So the reported price was $0.40 at close. That's per ADR right? In which case $0.20 per share, a bit over 14p.
Two separate entities so as bobsson says ,probably on Accustem website.
Yes absolutely though given that there is a commonality in the management and ownership and for max publicity it wouldn't surprise me if there was a bit of cross-fertilisation of good news.
Might be an RNS but just not on the TILS site see 2nd July RNS. So if you see it please share it. But any news will be on the Accustem website.
Thanks it is becoming clearer. A UK entitled TILS shareholder should divide their entitlement by 2 to see how many ADS (American Depository Shares) they will receive when ACMSY (US Ticker?) lists on NASDAQ. One ADS equals two shares in Accustem.
My hunch is Accustem will be sold before NASDAQ listing and Crest accounts will be credited with cash.
Why not an RNS? It's a UK company, just not traded on the UK markets.
All news regarding Accustem will be published on its newish UK website?
Yes I agree so About 21cents so far per Uk share.But if news occurs I would suspect a sharp rise, but how they realease that news I have no idea!!
Yes I remember now, OTC doesn't have the NASDAQ requirements and is widely used for foreign companies to trade in the US. I suppose it's a junior market and once a company can qualify under one of the NASDAQ definitions it could, I suppose, graduate - but presumably still trading in ADRs as it remains a foreign owned company.
I don't think the qualifications for trading on OTC are very high at all - no history etc, so I suspect the prices we can see are actual traded prices.
Trading history I think means share trading, and to be fair I thought how do you get a trading history , well on the OTCPK apparently and so I’ve been informed a lot of global companies trade on OTC and as OTC is apparently easy to trade on for a company it’s the obvious way to go.
Cloudy we've been round this one in depth twice recently to my knowledge. They don't meet any of the requirements as far as I remember but then Accustem shares are not being listed on the NASDAQ as such, but ADRs are - and I think I ended up thinking that must be the loophole which precludes them from the listing requirements. ISTR someone found some categories which bypass them anyway.
For sure Accustem won't have a trading history for maybe years as right now we have no products...
I will just edit the previous, I think Barclays will sell my NASDAQ shares and credit my UK ISA account. I have not heard anything from Barclays since TILS advised they were only going to list on the NASDAQ.
Thanks Bluebelly. Currently 0.4275 cents? So UK entitled ex TILS shareholders await either their accounts being credited with a dummy Crest credit of ACCU shares, or notification from their Broker that they hold a Crest credit on behalf of their client. I already know that Barclays will sell my shares as soon as they list on NASDAQ and my ISA account will be credited with the proceeds of sale.
But I would not recommend the BB.
Try
https://uk.advfn.com/stock-market/USOTC/ACMSY/share-price?java=1
Well I think it’s not doing to bad, a bit of news on Accustem would make this fly I suspect. As after the confirmation from royal Marsden and eminent Italian institute a while ago, a bit of news now would not go amiss.
https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy
No real volume.
I don't know how many have access to the Pinks.
BB
Just changing the thread header, because Accustem is what we are discussing. So first question, is Accustem (ACCU) definitely trading on the OTC (over the counter) market on the NASDAQ? If so what are the shares currently trading at, and is there much volume?